Hydroxyapatite Microparticles for Tumor Antigen Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy methods for cancer treatment, such as pharmacological substances, specific antibodies, and T-cell stimulation, face limitations due to toxicity, antigenic variability of tumor cells, and complex purification protocols for heat shock proteins, making it difficult to effectively stimulate a specific immune response against tumors.
Innovation Solution
A method using biocompatible mineral microparticles, like hydroxyapatite, to selectively adsorb and vectorize tumor antigens, allowing for a single-step purification and recognition by the immune system, combined with a cofactor derived from tumor extracts to enhance immune response, simplifying the preparation of tumor antigens for immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If heat shock proteins are used as adjuvants in immunotherapy, then immune response stimulation is improved, but purification protocol complexity increases
Solution Approach 1:
The patent uses heat shock proteins as intermediary molecules that naturally bind to tumor antigens and serve as adjuvants. These proteins act as mediators between the tumor antigens and the immune system, facilitating antigen presentation to T-cells while simultaneously providing immunostimulatory signals through their adjuvant activity.
Solution Approach 2:
The patent extracts heat shock proteins from tumor cells through a simplified purification process. By focusing on extracting only the heat shock proteins and associated antigens rather than purifying entire tumor cell lysates, the method reduces complexity while maintaining immunotherapy effectiveness.
2Reliability
If tumor antigens are purified for autologous immunotherapy, then treatment specificity is improved, but preparation time and complexity increase
Solution Approach 1:
The patent performs preliminary extraction of heat shock proteins from tumor cells before final antigen preparation. By pre-isolating the heat shock proteins that naturally bind antigens, the method prepares the immunotherapeutic agent in advance, reducing the time required for final antigen purification and assembly.
Solution Approach 2:
The patent uses a universal approach where heat shock proteins from any tumor type can serve as adjuvants for their associated antigens. This multi-functional system allows the same heat shock protein extraction protocol to be applied across different cancer types, streamlining the preparation process while maintaining patient-specific antigen specificity.
3Manufacturing precision
If multiple purification steps are used for tumor antigens, then antigen purity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent extracts tumor antigens associated with heat shock proteins using a focused extraction protocol that targets only the heat shock protein-antigen complexes. This selective extraction removes unnecessary components from tumor cell lysates, achieving high antigen purity without requiring multiple sequential purification steps.
Solution Approach 2:
The patent creates a composite therapeutic agent consisting of heat shock proteins naturally bound to tumor antigens. This composite structure allows simultaneous purification of both the adjuvant (heat shock protein) and the antigen in a single process, eliminating the need for separate purification steps while maintaining high purity of both components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the effective purification and presentation of tumor antigens to the immune system, stimulating a specific immune response and attracting antigen-presenting cells, potentially leading to improved cancer treatment outcomes with reduced toxicity and increased efficacy.
Implementation Method 1
biocompatible mineral (e.g. hydroxyapatite) or polymeric microparticles... selectively adsorb and vectorize tumor antigens
Data Source
AI summary
The invention relates to a medicament characterized in that it comprises at least one solid biocompatible support, preferably in powder form, on which at least one active substance, preferably selected among biological materials and/or biological molecules, is adsorbed or on which it is to be adsorbed, preferably without requiring a coupling agent. Said solid biocompatible support is capable of purifying the active substance. The invention relates to also relates to a method for preparing a medicament of the aforementioned type, this method essentially consisting of placing at least one solid biocompatible support, preferably in powder form, in contact with at least one active substance, preferably selected among biological materials and/or biological molecules, in such a manner that the active substance is reversibly adsorbed and without denaturing on the support.